Connect Biopharma (CNTB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.0M

Revenue (quarter)

$2.8M

Revenue growth (year over year)

+5666.67%

Gross profit (trailing twelve months)

$3.0M

Gross margin

100.00%

Net income (trailing twelve months)

−$69.0M

Net income (quarter)

−$17.3M

Net income growth (year over year)

−33.99%

Net margin

−2336.30%

Return on equity

−140.51%

EPS (trailing twelve months)

−$1.19

Book value per share

$0.43

P/E (trailing twelve months)

—

Price to book

2.15

Debt to assets

38.21%

Payout ratio

—

Dividend yield

—

Company profile

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

• Is Connect Biopharma (CNTB) profitable?

  No. Connect Biopharma reported a net loss of $69.0M over the trailing twelve months.

• How much revenue does Connect Biopharma (CNTB) make?

  Connect Biopharma generated $3.0M in revenue over the trailing twelve months, up 5666.67% year over year.

• How do I buy stock in Connect Biopharma (CNTB)?

  CNTB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.